Browse

(A) combination treatment of glycolytic inhibitor and reactive oxygen stress enhancer in Sorafenib-resistant and high metastatic potential hepatocellular carcinoma cells
간암에서 소라페닙 저항성 및 전이성 세포에 대한 해당과정 억제제 및 활성산소 촉진제의 병용치료 효과

Cited 0 time in Web of Science Cited 0 time in Scopus
Authors
이민종
Advisor
김윤준
Major
의과대학 임상의과학과
Issue Date
2016-02
Publisher
서울대학교 대학원
Keywords
3-bromopyruvateButhionine sulfoximineHepatocellular carcinomaAnoikis-resistant cell
Description
학위논문 (박사)-- 서울대학교 대학원 : 의과대학 임상의과학과 전공, 2016. 2. 김윤준.
Abstract
BACKGROUND & AIM: Acquisition of anoikis resistance (AR) is a prerequisite for the metastasis in hepatocellular carcinoma (HCC). However, little is known about how energy metabolism and antioxidant system are changed in HCC AR cells. We aimed to evaluate the anti-tumor effect of a combination treatment of 3-bromopyruvate (3-BP), an inhibitor for glycolysis, and buthionine sulfoximine (BSO), an inhibitor for glutathione synthesis in HCC AR cells.
METHODS: We compared glycolysis, reactive oxygen species (ROS) production, and chemoresistance among Huh-BAT, HepG2 human HCC cells, and corresponding AR cells. Expression of hexokinase II, gamma-glutamylcystine synthetase (rGCS), and epithelial–mesenchymal transition markers in AR cells was assessed. Anti-tumor effect of a combination treatment of 3-BP and BSO were evaluated in AR cells and HCC xenograft mouse model.
RESULTS: AR cells showed a significantly higher chemoresistance, glycolysis, and lower ROS production than attached cells. Expression of hexokinase II, rGCS, and Snail was higher in HCC AR cells than attached cells. A combination treatment of 3-BP and BSO effectively suppressed proliferation of HCC AR cells through apoptosis induction by blocking glycolysis and enhancing ROS levels. In a xenograft mouse model, tumors induced from HCC AR cells more rapidly grew than HCC attached cells. Growth rates of tumors derived from HCC AR cells were significantly suppressed in the group treated with 3-BP and BSO as compared to the group treated with 3-BP or sorafenib alone.
CONCLUSIONS: These results demonstrate that a combination treatment of 3-BP and BSO has a synergistic anti-tumor effect in HCC AR model. This strategy might be an effective adjuvant therapy to patients with sorafenib-resistant HCC.
Language
English
URI
https://hdl.handle.net/10371/121821
Files in This Item:
Appears in Collections:
College of Medicine/School of Medicine (의과대학/대학원)Dept. of Clinical Medical Sciences (임상의과학과)Theses (Ph.D. / Sc.D._임상의과학과)
  • mendeley

Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse